<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570137</url>
  </required_header>
  <id_info>
    <org_study_id>FiberStudy</org_study_id>
    <nct_id>NCT04570137</nct_id>
  </id_info>
  <brief_title>Fiber Fermentation Study</brief_title>
  <official_title>Effects Dietary Fiber From Grains or Fruits and Vegetables on the Intestinal Production of Short-chain Fatty Acids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hohenheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hohenheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to better understand the interplay between the intake of dietary&#xD;
      fiber and intestinal bacteria, their metabolic activity and the effect on the intestinal&#xD;
      barrier.&#xD;
&#xD;
      The effect of two different dietary fiber supplements is tested (arabinoxylan &amp; ß-glucan&#xD;
      versus inulin &amp; fructooligosaccharides) in a randomized crossover intervention trial&#xD;
      including healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-armed crossover trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-chain fatty acids (SCFAs)</measure>
    <time_frame>Will be measured in approx. 4 weeks after study completion.</time_frame>
    <description>SCFAs in native fecal samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome composition</measure>
    <time_frame>Will be measured in approx. 6-8 weeks after study completion.</time_frame>
    <description>16S NGS sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut barrier integrity</measure>
    <time_frame>Will be measured in approx. 4 weeks after study completion.</time_frame>
    <description>Lipopolysaccharide-binding protein (plasma) and zonulin (feces)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Intestinal Health</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm received the arabinoxylan/ß-glucan mix first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm received the inulin/oligofructose mix first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary fiber supplementation</intervention_name>
    <description>16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)&#xD;
16g/day: mix of 50% inulin and 50% oligofructose from chicory</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years&#xD;
&#xD;
          -  signed written informed consent&#xD;
&#xD;
          -  willingness not to change the dietary pattern in the course of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI below 18 or above 30&#xD;
&#xD;
          -  acute or chronic gastrointestinal symptoms&#xD;
&#xD;
          -  neoplastic diseases&#xD;
&#xD;
          -  very strict diets, including raw foodists and frutarians&#xD;
&#xD;
          -  regular smoking (more than one box per day)&#xD;
&#xD;
          -  intake of antibiotics, immunosuppressants, or any intestinal therapeutics three months&#xD;
             prior to study begin&#xD;
&#xD;
          -  supplementation of fibers three months prior to study begin&#xD;
&#xD;
          -  simultaneous participation in another clinical study&#xD;
&#xD;
          -  pregnancy / breastfeeding&#xD;
&#xD;
          -  relevant violations of the study protocol&#xD;
&#xD;
          -  intolerance to the fiber supplements (including wheat, oat, chicory)&#xD;
&#xD;
          -  occurrence of relevant diseases (individual decision by study physicians)&#xD;
&#xD;
          -  revocation of consent&#xD;
&#xD;
          -  placement in a clinic or similar facility based on an official or court order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan C Bischoff, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hohenheim, Institute of Nutritional Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Nutritional Medicine, University of Hohenheim</name>
      <address>
        <city>Stuttgart</city>
        <zip>70599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hohenheim</investigator_affiliation>
    <investigator_full_name>Stephan C. Bischoff, MD, Professor</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Gastroenterology</keyword>
  <keyword>Gut microbiome</keyword>
  <keyword>Gut barrier</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

